Table 3.
Prediction performance of maternal plasma angiogenic and anti-angiogenic factors concentrations and ratios (at 24–28 weeks of gestation) for subsequent fetal death (from 24–37.6 weeks of gestation).
| Predictor | Cutoff* | Relative Risk | AUC | Sensitivity | Specificity | Likelihood ratio (+) | Likelihood ratio (−) |
|---|---|---|---|---|---|---|---|
| sVEGFR1 | >90 | 9.4 (2.9–31.1) |
0.85 | 0.55 (0.23–0.83) |
0.89 (0.87–0.91) |
4.9 (2.8–8.7) |
0.51 (0.27–0.98) |
| sVEGFR1 | >97.5 | 10.8 (2.8–41.4) |
0.85 | 0.27 (0.06–0.61) |
0.97 (0.95–0.98) |
8.4 (3–23.5) |
0.75 (0.52–1.08) |
| sEng | >90 | 14 (4.1–48.3) |
0.82 | 0.64 (0.31–0.89) |
0.89 (0.87–0.91) |
5.9 (3.6–9.5) |
0.41 (0.19–0.89) |
| sEng | >97.5 | 27.4 (8.2–91.2) |
0.82 | 0.55 (0.23–0.83) |
0.96 (0.94–0.97) |
13.7 (7.3–25.8) |
0.47 (0.25–0.9) |
| PlGF | <10 | 7.7 (2.3–25.5) |
0.73 | 0.55 (0.23–0.83) |
0.87 (0.84–0.89) |
4.1 (2.3–7.2) |
0.52 (0.27–1) |
| PlGF | <2.5 | 16.7 (5–55.4) |
0.73 | 0.45 (0.17–0.77) |
0.95 (0.94–0.97) |
9.9 (4.8–20.3) |
0.57 (0.33–0.98) |
| PlGF/sVEGFR1 | <10 | 13.7 (4–47.1) |
0.79 | 0.64 (0.31–0.89) |
0.89 (0.87–0.91) |
5.7 (3.5–9.3) |
0.41 (0.19–0.89) |
| PlGF/sVEGFR1 | <2.5 | 29.1 (8.8–97.1) |
0.79 | 0.55 (0.23–0.83) |
0.96 (0.95–0.97) |
14.6 (7.7–27.7) |
0.47 (0.25–0.9) |
| PlGF/sEng | <10 | 12 (3.5–41.1) |
0.77 | 0.64 (0.31–0.89) |
0.87 (0.85–0.9) |
5.1 (3.1–8.2) |
0.42 (0.19–0.91) |
| PlGF/sEng | <2.5 | 27.4 (8.2–91.2) |
0.77 | 0.55 (0.23–0.83) |
0.96 (0.94–0.97) |
13.7 (7.3–25.8) |
0.47 (0.25–0.9) |
Data is presented as pecentile for cutoff values; as number( 95% confidence interval) for sensitivity, specificity and likelihood ratios. sVEGFR-1- soluble vascular endothelial growth factor receptor -1;sEng- soluble endoglin; PlGF- placental growth factor; AUC: the Area Under the Receiver Operating Characteristic curve.